Wells Fargo analyst Derek Archila upgrades Kymera Therapeutics (NASDAQ:KYMR) from Equal-Weight to Overweight and raises the price target from $38 to $57.
Wells Fargo Upgrades Kymera Therapeutics to Overweight, Raises Price Target to $57
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.